Pila Pharma AB (PILA) - Total Assets
Based on the latest financial reports, Pila Pharma AB (PILA) holds total assets worth Skr16.22 Million SEK (≈ $1.75 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See PILA book value for net asset value and shareholders' equity analysis.
Pila Pharma AB - Total Assets Trend (2015–2025)
This chart illustrates how Pila Pharma AB's total assets have evolved over time, based on quarterly financial data.
Pila Pharma AB - Asset Composition Analysis
Current Asset Composition (December 2025)
Pila Pharma AB's total assets of Skr16.22 Million consist of 99.6% current assets and 0.4% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 98.0% |
| Accounts Receivable | Skr255.00K | 1.6% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr0.00 | 0.0% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2015–2025)
This chart illustrates how Pila Pharma AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Pila Pharma AB.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Pila Pharma AB's current assets represent 99.6% of total assets in 2025, an increase from 87.3% in 2015.
- Cash Position: Cash and equivalents constituted 98.0% of total assets in 2025, up from 83.9% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 12.0% in 2015.
- Asset Diversification: The largest asset category is accounts receivable at 1.6% of total assets.
Pila Pharma AB Competitors by Total Assets
Key competitors of Pila Pharma AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.26 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.64 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $486.17 Million |
|
Xiangxue Pharmaceutical
SHE:300147
|
China | CN¥7.36 Billion |
Pila Pharma AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 11.26 | 5.21 | 1.04 |
| Quick Ratio | 11.26 | 5.21 | 1.04 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr14.72 Million | Skr4.05 Million | Skr87.09K |
Pila Pharma AB - Advanced Valuation Insights
This section examines the relationship between Pila Pharma AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.44 |
| Latest Market Cap to Assets Ratio | 0.49 |
| Asset Growth Rate (YoY) | 160.6% |
| Total Assets | Skr16.22 Million |
| Market Capitalization | $8.01 Million USD |
Valuation Analysis
Below Book Valuation: The market values Pila Pharma AB's assets below their book value (0.49x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Pila Pharma AB's assets grew by 160.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Pila Pharma AB (2015–2025)
The table below shows the annual total assets of Pila Pharma AB from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr16.22 Million ≈ $1.75 Million |
+160.57% |
| 2024-12-31 | Skr6.22 Million ≈ $669.80K |
-26.39% |
| 2023-12-31 | Skr8.46 Million ≈ $909.96K |
-22.33% |
| 2022-12-31 | Skr10.89 Million ≈ $1.17 Million |
-65.78% |
| 2021-12-31 | Skr31.81 Million ≈ $3.42 Million |
+492.67% |
| 2020-12-31 | Skr5.37 Million ≈ $577.60K |
-32.42% |
| 2019-12-31 | Skr7.94 Million ≈ $854.75K |
+8.57% |
| 2018-12-31 | Skr7.32 Million ≈ $787.24K |
-2.72% |
| 2017-12-31 | Skr7.52 Million ≈ $809.27K |
+482.82% |
| 2016-12-31 | Skr1.29 Million ≈ $138.85K |
+232.73% |
| 2015-12-31 | Skr387.78K ≈ $41.73K |
-- |
About Pila Pharma AB
Pila Pharma AB (publ) operates as a clinical stage biotech company in Sweden. The company develops XEN-D0501, a TRPV1 antagonist in Phase 2a trial for obesity, diabetes, and heart failure; Phase 1 trial for erythromelalgia, inflammation pain, and rare diseases; and preclinical trial for abdominal aorta aneurism and cardiovascular diseases. Pila Pharma AB (publ) was incorporated in 2014 and is hea… Read more